CD8A and neoplasm: MC38-bearing mice treated with a single dose of CD8-mIL2 at day 8 demonstrated dose-dependent antitumor activity, with most mice (7/10) achieving durable tumor rejection at 1 mg/kg (Fig. 4C and D).